DUBLIN--(BUSINESS WIRE)--The "Community Acquired Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H2 2020, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
The latest pipeline guide provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Community Acquired Pneumonia pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 7, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Phase 0 stages comprises 1 molecules, respectively.
The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
- The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Community Acquired Pneumonia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia
Key report benefits:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Community Acquired Pneumonia - Overview
- Community Acquired Pneumonia - Therapeutics Development
- Community Acquired Pneumonia - Therapeutics Assessment
- Community Acquired Pneumonia - Companies Involved in Therapeutics Development
- Community Acquired Pneumonia - Drug Profiles
- Community Acquired Pneumonia - Dormant Projects
- Community Acquired Pneumonia - Discontinued Products
- Community Acquired Pneumonia - Product Development Milestones
- Basilea Pharmaceutica Ltd
- Beijing Fogangren Bio-Pharm Tech Co Ltd
- BioAegis Therapeutics Inc
- Biotest AG
- Combioxin SA
- InflaRx NV
- ioGenetics Inc
- Iterum Therapeutics Plc
- Kyorin Pharmaceutical Co Ltd
- La Jolla Pharmaceutical Company
- Meiji Seika Pharma Co Ltd
- Merck & Co Inc
- Nabriva Therapeutics Plc
- Paratek Pharmaceuticals Inc
- ProThera Biologics Inc
- TaiGen Biotechnology Co Ltd
- Takeda Pharmaceutical Co Ltd
- Wockhardt Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/oyiw4m
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.